Baudi et al.1 described the first example of a founder BRCA1 (MIM 113705) mutation specific to the Italian population. They studied 24 patients from unrelated breast/ovarian cancer families from the southern region of Calabria and found the 5083del19 mutation to be present four times. This single mutation accounted for four of the six BRCA1 mutations detected in the study. Haplotype analysis confirms the 5083del19 mutation to be a founder mutation. Here we present data on Italian breast/ovarian cancer families in North America, and ask whether or not this mutation is observed in these families.
Founder mutations in BRCA1 and BRCA2 (MIM 600185) have been described in several Western European countries, but, to date, no population has demonstrated founder effects as striking as those observed for Icelandic and the Ashkenazi Jewish groups.2,3,4 Table 1 summarises the different BRCA1 or BRCA2 mutations that have been reported in more than one family from various studies and regions of Italy. To date, only the BRCA1 5083del19 mutation is recurrent and specific to individuals of Italian descent; most mutations are also found in other European countries.
At the Sunnybrook & Women's College Health Sciences Centre in Toronto, Canada, we evaluated DNA samples for germline mutations in BRCA1 and BRCA2 from 116 women with primary cancers of the breast or ovary, and with at least one parent with Italian ancestry. The 116 women participated in genetic studies for either clinical (high-risk families) or research (unselected patients) purposes. A variety of methods were employed for mutation analysis. All samples were tested for deleterious mutations in exons 10 and 11 of BRCA2 and exons 2, 5, 11, 16, 20 and exon 13 duplication of BRCA1. This testing covered the majority of mutations described previously for Italian patients (Table 1), revealing 29 of the 39 mutations (Table 2). Subsequent testing by direct sequencing (by Myriad Genetic Laboratories) revealed ten additional mutations in other exons.
Thirty-nine BRCA1 or BRCA2 mutations were identified among the 116 families (33.6%); 23 in BRCA1 and 16 in BRCA2 (Table 2). In total, 19 of the 39 mutations (48.7%) were present in more than one family. Of particular significance was the detection of the BRCA1 exon 16 5083del19 in five families. Three of these five families, who provided specific information about their ancestry, indicated that they originated from Calabria. The 5083del19 mutation accounted for 21.7% of all BRCA1 mutations. Seven other mutations were identified in two families each, including the BRCA1 3875del4, 5382insC and the BRCA2 6696delTC previously described in Italian studies. We did not detect two BRCA1 mutations reported in multiple families in Italy (T300G (C61G) and 1499insA).
In a recent study of 649 unselected ovarian cancer patients in Canada, Risch et al.5 reported that the highest BRCA mutation frequency (24.1%) was among women of Italian ancestry (for non-Jewish subjects). In our study of 116 women of Italian ancestry diagnosed with breast or ovarian cancer, one-third were carriers of mutations in BRCA1 or BRCA2; this mutation frequency is likely an underestimate, as we did not screen all patients for all possible mutations in these genes. In the past, research centres have focused on the exon 11 region of the BRCA1 gene, and interestingly 16 of the 23 BRCA1 mutations identified in Italian families were outside of exon 11. Our data confirms the BRCA1 exon 16 5083del19 mutation to be a founder mutation in the Italian population (from Calabria), in North America as well as in Italy. It may be prudent to screen for recurrent mutations prior to undertaking a full genetic screen in families of Italian origin.
Electronic Database Information
Accession numbers and URLs for data in this article are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www3.ncbi.nlm.nih.gov/Omim/, for inherited breast cancer type 1 and ovarian cancer [MIM 113705] and for inherited breast cancer type 2 [MIM 600185].
Breast Cancer Information Core Database (BIC), http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/, for information on sequence alterations in BRCA1 and BRCA2.
References
Baudi F et al. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer Hum Mutat 2001 18: 163–164
Johannesdottir G et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients Cancer Res 1996 56: 3663–3665
Struewing JP et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals Nature Genet 1995 11: 198–200
Roa BB et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 Nature Genet 1996 14: 185–7
Risch HA et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 2001 68: 700–710
Ottini L et al. BRCA1 and BRCA2 mutations in central and southern Italian patients Breast Cancer Res 2000 2: 307–710
Turchetti D et al. BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer Eur J Cancer 2000 36: 2083–2089
De Benedetti VM et al. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online Hum Mutat 1998 12: 215
Caligo MA et al. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations Oncogene 1996 13: 1483–1488
De Benedetti VM et al. Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test Oncogene 1996 13: 1353–1357
Santarosa M et al. Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer Int J Cancer 1998 78: 581–786
Montagna M et al. Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families Cancer Res 1996 56: 5466–5469
Montagna M et al. Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families Oncogene 1999 18: 4160–4165
Ottini L et al. Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred Hum Mutat 1998; Suppl: S237–S239
Santarosa M et al. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy Int J Cancer 1999 83: 5–9
Pisano M et al. Identification of a founder BRCA2 mutation in Sardinia Br J Cancer 2000 82: 553–559
Acknowledgements
We thank the Familial Ovarian Tumour Study group (FOTS: Risch et al 2001) for contributing data for this report. Alexander Liede's doctoral studies are supported by the Canadian Institutes of Health Research (formerly MRC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nedelcu, R., Liede, A., Aubé, J. et al. BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet 10, 150–152 (2002). https://doi.org/10.1038/sj.ejhg.5200755
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5200755
This article is cited by
-
High Resolution Melting Analysis is Very Useful to Identify Breast Cancer Type 1 Susceptibility Protein (BRCA1) c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA
Molecular Diagnosis & Therapy (2017)
-
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family
Familial Cancer (2010)
-
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
EPMA Journal (2010)
-
A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population
BMC Cancer (2009)
-
Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
Breast Cancer Research and Treatment (2009)